Professor Tim Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times. 

Dr David Shepherd is a Lead Production Engineer and Materials Specialist at Eudaemon Technologies. His journey began at the University of Wollongong, where he pursued advanced studies and eventually obtained a PhD under the guidance of a distinguished professor. His research initially focused on actuating materials and artificial muscles, particularly centred around hydrogel materials. These early explorations have seamlessly evolved into his current focus on utilising hydrogels in the realm of sexual reproductive health, with a specific emphasis on developing innovative hydrogel condoms.

Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.

By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.